€39.40
0.90%
Xetra, Sep 30, 12:49 pm CEST. Market open.
ISIN
DE000A2GS5D8
Symbol
DMP
Index

Dermapharm Stock price

€39.05
+0.05 0.13% 1M
-4.85 11.05% 6M
-0.30 0.76% YTD
+6.55 20.15% 1Y
-0.07 0.18% 3Y
-43.80 52.87% 5Y
+13.05 50.19% 10Y
+13.05 50.19% 20Y
Xetra, Closing price Tue, Sep 29 2026
-0.30 0.76%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Industry

AI Insights on Dermapharm Insights AI Insights on Dermapharm

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
€1.9b
Enterprise Value
€2.9b
Net debt
€945.4m
Cash
€223.6m
Shares outstanding
49.5m
Valuation (TTM | estimate)
P/E
13.2
P/S
1.7 | 1.6
EV/Sales
2.5 | 2.4
EV/FCF
13.4
P/B
3.6
Dividends
DPS
€0.88
Yield 1Y | 5Y
2.3% | 2.5%
Growth 1Y | 5Y
-2.2% | 0.0%
Payout 1Y | 3Y
35.8% | 46.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€1.2b | €1.2b
EBITDA
€330.2m
EBIT
€234.4m
Net Income
€146.5m
Free Cash Flow
€216.0m
Growth (TTM | estimate)
Revenue
0.4% | 4.3%
EBITDA
8.1%
EBIT
7.4%
Net Income
36.7%
Free Cash Flow
23.2%
Margin
Gross
68.1%
EBITDA
28.0%
EBIT
19.8%
Net
12.4%
Free Cash Flow
18.3%
Financial Health
Equity Ratio
31.8%
Return on Equity
19.1%
ROCE
13.1%
ROIC
10.3%
Debt/Equity
2.2
More
EPS
€3.0
FCF per Share
€4.4
Short interest
-
Employees
4k
Rev per Employee
€330.0k

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Dermapharm forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Dermapharm forecast:

Buy
78%
Hold
22%

Financial data from Dermapharm

Jun '26
+/-
%
1,181 1,181
0% 0%
100%
- Direct Costs 376 376
7% 7%
32%
805 805
4% 4%
68%
- Selling and Administrative Expenses 299 299
4% 4%
25%
- Research and Development Expense - -
-
-
330 330
8% 8%
28%
- Depreciation and Amortization 96 96
10% 10%
8%
EBIT (Operating Income) EBIT 234 234
7% 7%
20%
Net Profit 147 147
37% 37%
12%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Dr. Feldmeier
Employees 3,503
Founded 1991
Website ir.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today